Intratumoral injection of SD-101 + ipilimumab + radiation
15 patients will be enrolled in the phase II expanded cohort at the chosen ipilimumab dose. All patients initially receive two fractions of 2 Gy radiation. After radiation, patients receive intratumoral SD-101 (1mg) and ipilimumab (10mg or 25mg depending on dose cohort). Weekly SD-101 intratumoral injections continue for a total of 5 doses.